Jump to content

Search results

  • Thumbnail for Novo Nordisk
    Novo Nordisk (category Pharmaceutical companies established in 1923)
    35 billion. In November 2021, Novo announced it would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share)...
    42 KB (3,975 words) - 03:01, 7 November 2024
  • hyperoxaluria. It is an LDHA-directed small interfering RNA developed by Dicerna Pharmaceuticals. The most common side effects include injection site reactions...
    9 KB (560 words) - 03:18, 15 July 2024
  • Thumbnail for Small interfering RNA
    pipeline of siRNA therapies are Dicerna Pharmaceuticals, partnered Eli Lilly and Company and Arrowhead Pharmaceuticals partnered with Johnson and Johnson...
    56 KB (6,837 words) - 04:51, 29 October 2024
  • Thumbnail for RNA interference
    that are being developed by pharmaceutical companies such as Arrowhead Pharmaceuticals, Dicerna, Alnylam Pharmaceuticals, Amgen, and Sylentis. These medications...
    140 KB (15,409 words) - 08:23, 28 October 2024
  • Thumbnail for Gene therapy
    necessarily non-viral delivery problems. Alnylam, Dicerna Pharmaceuticals, and Ionis Pharmaceuticals focus on delivery of siRNA (antisense oligonucleotides)...
    176 KB (18,235 words) - 06:24, 10 November 2024
  • forward to initial public offering a number of firms, including Dicerna Pharmaceuticals and Clovis Oncology. The firm has also provided funding to support...
    9 KB (808 words) - 10:20, 19 August 2024